Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Sep 28:7:109-125.
doi: 10.2147/DNND.S109251. eCollection 2017.

Current concepts in multiple sclerosis therapy

Leslie Sedal  1 , Antony Winkel  1 , Joshua Laing  1 , Lai Yin Law  1 , Elizabeth McDonald  1
Affiliations
Review

Current concepts in multiple sclerosis therapy

Leslie Sedal et al. Degener Neurol Neuromuscul Dis. .

Abstract

Over the past 20 years, the available therapies for multiple sclerosis have expanded exponentially. With several more agents likely to be approved for public funding in Australia in the next 12 months on top of the existing multitude of Australian Pharmaceutical Benefits Scheme-subsidized therapies, the choice is becoming even more complex. This review summarizes the current state of available therapies and anticipates likely future directions, including an important focus on contemporary symptom management. For each agent, the major trials, side effects, and clinical utility are summarized, with a particular focus on the Australian experience of these therapies. It is hoped this review provides an up-to-date reference of the exciting current state of multiple sclerosis therapy.

Keywords: DMDs; NEDA; PML; demyelination; disease modifying drugs; no evidence of disease activity; progressive multifocal leukoencephalopathy.

PubMed Disclaimer

Conflict of interest statement

Disclosure Over the last 3-years, Dr Sedal has attended many meetings in Melbourne and Sydney to hear Australian and overseas speakers discuss various aspects of MS therapy. These meetings and speakers have been sponsored by all the companies with products in the field. Dr Sedal has been involved in many clinical trials, the most recent being the ocrelizumab trial in primary progressive MS. He received funding from Roche to attend a 1-day meeting of the Advisory board held in Sydney in early 2016. The other authors of this paper have nothing to declare and report no conflicts of interest in this work.

References

    1. Vasconcelos CC, Aurenção JC, Thuler LC, Camargo S, Alvarenga MP, Alvarenga RM. Prognostic factors associated with long-term disability and secondary progression in patients with multiple sclerosis. Mult Scler Relat Disord. 2016;8:27–34. - PubMed
    1. Leocani L, Rocca MA, Comi G. MRI and neurophysiological measures to predict course, disability and treatment response in multiple sclerosis. Cur Opin Neurol. 2016;29:243–253. - PubMed
    1. Giovannoni G. Multiple sclerosis should be treated using a step-down strategy rather than a step-up strategy – yes. Mult Scler. 2016;22:1397–1400. - PubMed
    1. Naismith RT. Multiple sclerosis should be treated using a step-down strategy rather than a step-up strategy – no. Mult Scler. 2016;22:1400–1402. - PubMed
    1. Członkowska A, Smoliński Ł, Litwin T. Severe disease exacerbations in patients with multiple sclerosis after discontinuing fingolimod. Neurol Neurochir Pol. 2017;51:156–162. - PubMed

LinkOut - more resources